21
Participants
Start Date
April 30, 2009
Primary Completion Date
June 30, 2011
Study Completion Date
September 30, 2011
IV CP-4126
1250 mg/m2/d, IV (in the vein) on day 1, 8 and 15 of each 4 week cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Clinique d'Oncologie Médicale, Institut Jules Bordet, Brussels
Oslo University Hospital, The Norwegian Radium Hospital,, Oslo
Oslo University Hospital, Ullevål, Oslo
Lead Sponsor
Clavis Pharma
INDUSTRY